STAG2 and myeloid neoplasm: The cohesin complex, comprising SMC1, SMC3, RAD21, and either STAG1 or STAG2, is a recurrent mutational target, with STAG2 (stromal antigen 2) mutations accounting for more than half of cohesin mutations in myeloid malignancies [63].